FDA批准全球“双下巴”溶脂针Kybella,去双下巴一针见效!

2015-05-07 佚名 生物谷

昨晚,老夫夜观天象,发现西方有紫气升腾,乃大喜之兆。果不其然,噼里啪啦一顿惊雷,一款去“双下巴”的革命性美容产品在美帝横空出世,此乃广大爱美人士之大福祉也!东方的“肥下巴”美人儿们,都抓紧儿的,该办护照办护照,该办签证办签证,下半年一起飞赴美帝,去--掉--双--下--巴!! “双下巴”确实非常恼人,它是广大爱美人士心中抹不去的痛。在医学上,这块讨人厌的肥肉有个学名叫“颏下脂肪(subm

昨晚,老夫夜观天象,发现西方有紫气升腾,乃大喜之兆。果不其然,噼里啪啦一顿惊雷,一款去“双下巴”的革命性美容产品在美帝横空出世,此乃广大爱美人士之大福祉也!东方的“肥下巴”美人儿们,都抓紧儿的,该办护照办护照,该办签证办签证,下半年一起飞赴美帝,去--掉--双--下--巴!!

“双下巴”确实非常恼人,它是广大爱美人士心中抹不去的痛。在医学上,这块讨人厌的肥肉有个学名叫“颏下脂肪(submental fat)”,这块肉非常难搞,任凭怎么减肥也很难去掉。目前为止,祛除双下巴最有效的手段是吸脂。不过别急,近日美容行业诞生了一款革命性的产品,非常神奇,去双下巴一针见效!

近日,FDA提前2周批准了全球首个“双下巴”溶脂针Kybella(ATX-101),用于中度至重度“双下巴”成人,该针剂是用于消除多余颏下脂肪(双下巴)的首个也是唯一一个非手术治疗产品。ATX-101是一种人造的脱氧胆酸(deoxycholic acid),这是人体内天然存在的一种物质,帮助分解脂肪。在临床试验中,相比安慰剂,ATX-101能够有效消除颏下脂肪并改善整体外观。此次批准,使ATX-101成为同类产品中首个获批用于美容目的的注射针剂。



Kybella的上市,将为“双下巴”人群提供一个高质量的非手术治疗选择,大部分患者注射2-4次后,即可取得满意的效果,少部分患者可能需要注射6次。不过需要注意的是,由于脱氧胆酸能摧毁所接触到的任何细胞,FDA仅批准Kybella用于颏下区脂肪组织,禁止用于其他部位。而且,Kybella只能由训练有素的医疗专业人员注射,当注射部位存在感染时禁止注射。另外,Kybella可能导致严重的副作用,包括下巴部位的神经损伤及面部肌无力。为了避免潜在的组织损伤,Kybella应避免注射入或接近(1-1.5厘米)唾液腺、淋巴结和肌肉等脆弱解剖结构。

据美国皮肤外科学会(ASDS)估计,约68%的美国人受“双下巴”困扰。另据美国美容整形外科医师协会(ASAPS)数据,2014年美国人在手术和非手术美容整形方面的支出超过120亿美元。Kybella作为美容行业一个真正创新的产品,市场潜力十分可观。业界预计,Kybella的年销售峰值将突破3亿美元。

Kybella由美国生物制药公司Kythera Biopharmaceuticals研发,该公司已计划从6月起开展医师培训,并在下半年将Kybella推向市场。正是因为对溶脂针Kybella在美容市场中的商业潜力十分有信心,Kythera公司去年以8400万美元的价格从前合作伙伴拜耳(Bayer)手中收回了ATX-101的全部权利。另外,Kythera公司也希望以此为契机打造一个美容产品管线,就在今年初,该公司与Actelion制药公司达成了一笔2700万美元的合作协议,共同开发一种失败了的抗炎症药物,而这种药物被认为有可能开发出一种治疗脱发的药物。

原始出处:

Damian Garde.Kythera bags FDA approval for its double-chin-shrinking shot.Fierce Biotech.April 29, 2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=82946, encodeId=4c8382946db, content=真是什么针都有啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Apr 26 23:14:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63637, encodeId=131f6363e5a, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63638, encodeId=14c26363874, content=学, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63639, encodeId=93b663639f4, content=习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839373, encodeId=bdaf18393e307, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Sep 30 09:14:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22896, encodeId=9ab822896ae, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:15:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22865, encodeId=0d34228655e, content=这不就是化尸水吗?打哪里化哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Thu May 07 16:21:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22859, encodeId=0c71228597a, content=坐等效果报告, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62371619927, createdName=xiaosanshu, createdTime=Thu May 07 11:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2016-04-26 1dd8c52fm63(暂无匿称)

    真是什么针都有啊!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=82946, encodeId=4c8382946db, content=真是什么针都有啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Apr 26 23:14:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63637, encodeId=131f6363e5a, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63638, encodeId=14c26363874, content=学, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63639, encodeId=93b663639f4, content=习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839373, encodeId=bdaf18393e307, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Sep 30 09:14:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22896, encodeId=9ab822896ae, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:15:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22865, encodeId=0d34228655e, content=这不就是化尸水吗?打哪里化哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Thu May 07 16:21:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22859, encodeId=0c71228597a, content=坐等效果报告, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62371619927, createdName=xiaosanshu, createdTime=Thu May 07 11:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2016-02-07 1de48a27m96(暂无匿称)

    了解

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=82946, encodeId=4c8382946db, content=真是什么针都有啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Apr 26 23:14:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63637, encodeId=131f6363e5a, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63638, encodeId=14c26363874, content=学, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63639, encodeId=93b663639f4, content=习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839373, encodeId=bdaf18393e307, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Sep 30 09:14:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22896, encodeId=9ab822896ae, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:15:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22865, encodeId=0d34228655e, content=这不就是化尸水吗?打哪里化哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Thu May 07 16:21:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22859, encodeId=0c71228597a, content=坐等效果报告, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62371619927, createdName=xiaosanshu, createdTime=Thu May 07 11:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=82946, encodeId=4c8382946db, content=真是什么针都有啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Apr 26 23:14:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63637, encodeId=131f6363e5a, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63638, encodeId=14c26363874, content=学, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63639, encodeId=93b663639f4, content=习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839373, encodeId=bdaf18393e307, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Sep 30 09:14:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22896, encodeId=9ab822896ae, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:15:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22865, encodeId=0d34228655e, content=这不就是化尸水吗?打哪里化哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Thu May 07 16:21:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22859, encodeId=0c71228597a, content=坐等效果报告, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62371619927, createdName=xiaosanshu, createdTime=Thu May 07 11:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=82946, encodeId=4c8382946db, content=真是什么针都有啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Apr 26 23:14:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63637, encodeId=131f6363e5a, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63638, encodeId=14c26363874, content=学, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63639, encodeId=93b663639f4, content=习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839373, encodeId=bdaf18393e307, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Sep 30 09:14:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22896, encodeId=9ab822896ae, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:15:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22865, encodeId=0d34228655e, content=这不就是化尸水吗?打哪里化哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Thu May 07 16:21:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22859, encodeId=0c71228597a, content=坐等效果报告, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62371619927, createdName=xiaosanshu, createdTime=Thu May 07 11:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2015-09-30 bugit
  6. [GetPortalCommentsPageByObjectIdResponse(id=82946, encodeId=4c8382946db, content=真是什么针都有啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Apr 26 23:14:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63637, encodeId=131f6363e5a, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63638, encodeId=14c26363874, content=学, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63639, encodeId=93b663639f4, content=习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839373, encodeId=bdaf18393e307, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Sep 30 09:14:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22896, encodeId=9ab822896ae, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:15:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22865, encodeId=0d34228655e, content=这不就是化尸水吗?打哪里化哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Thu May 07 16:21:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22859, encodeId=0c71228597a, content=坐等效果报告, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62371619927, createdName=xiaosanshu, createdTime=Thu May 07 11:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2015-05-07 huaxipanxing

    看看

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=82946, encodeId=4c8382946db, content=真是什么针都有啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Apr 26 23:14:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63637, encodeId=131f6363e5a, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63638, encodeId=14c26363874, content=学, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63639, encodeId=93b663639f4, content=习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839373, encodeId=bdaf18393e307, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Sep 30 09:14:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22896, encodeId=9ab822896ae, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:15:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22865, encodeId=0d34228655e, content=这不就是化尸水吗?打哪里化哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Thu May 07 16:21:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22859, encodeId=0c71228597a, content=坐等效果报告, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62371619927, createdName=xiaosanshu, createdTime=Thu May 07 11:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2015-05-07 sumer

    这不就是化尸水吗?打哪里化哪里

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=82946, encodeId=4c8382946db, content=真是什么针都有啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=145, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Tue Apr 26 23:14:00 CST 2016, time=2016-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63637, encodeId=131f6363e5a, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63638, encodeId=14c26363874, content=学, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=63639, encodeId=93b663639f4, content=习, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33591686340, createdName=1de48a27m96(暂无匿称), createdTime=Sun Feb 07 16:43:00 CST 2016, time=2016-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839373, encodeId=bdaf18393e307, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Wed Sep 30 09:14:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22896, encodeId=9ab822896ae, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:15:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22865, encodeId=0d34228655e, content=这不就是化尸水吗?打哪里化哪里, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Thu May 07 16:21:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22859, encodeId=0c71228597a, content=坐等效果报告, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62371619927, createdName=xiaosanshu, createdTime=Thu May 07 11:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2015-05-07 xiaosanshu

    坐等效果报告

    0